Related references
Note: Only part of the references are listed.The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients
S. Street et al.
ANNALS OF ONCOLOGY (2021)
Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase
Xuefeng Bai et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients
Edwin A. Basak et al.
THYROID (2020)
Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction
Anna Olsson-Brown et al.
ENDOCRINE CONNECTIONS (2020)
Immune checkpoint inhibitors-induced autoimmunity: The impact of gender
Paola Triggianese et al.
AUTOIMMUNITY REVIEWS (2020)
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities
Tim Cooksley et al.
SUPPORTIVE CARE IN CANCER (2020)
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
Ichiro Yamauchi et al.
PLOS ONE (2019)
Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis
H. K. Akturk et al.
DIABETIC MEDICINE (2019)
A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors
Patrick Arnaud-Coffin et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
Emma S. Scott et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
Hye In Kim et al.
ONCOIMMUNOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Priyanka C. Iyer et al.
THYROID (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Ichiro Yamauchi et al.
THYROID (2017)
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Hyunju Lee et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
D. L. Morganstein et al.
CLINICAL ENDOCRINOLOGY (2017)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Share Paper
